Please assess the completion status of the following clinical trial:

Trial Title: Effects of Topical Diclofenac on Tumor Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent has been signed prior to or at Screening Visit~* Caucasian male and female patients~* Age \> 18 years~* Negative pregnancy test in women of childbearing age~* Clinical diagnosis of actinic keratosis (AK)~* A minimum of three AK lesions~Exclusion Criteria in immunocompromised patients :~* Concomitant UV-phototherapy~* Pregnancy or lactation~* Women in child-bearing age who do not use highly efficient contraceptive methods (\<1% failure rate per year)~* Skin diseases that might interfere with response evaluation of study treatment~* Topical pretreatment of the AK study lesions with photodynamic therapy, Solaraze® 3% gel, Aldara®, 5-FU, or polyphenon E during the 8 weeks preceding study treatment~* Radiation therapy performed in the treatment area during the 3 months preceding study therapy~* Systemic treatment with diclofenac~* Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel~* Conditions that might interfere with the ability to understand the study and thus give written informed consent~* Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion~* Suspected lack of compliance~Exclusion criteria in immunocompetent patients:~* Concomitant UV-phototherapy~* Pregnancy or lactation~* Women in child-bearing age who do not use highly efficient contraceptive methods (\<1% failure rate per year)~* Patients with clinically relevant suppression of the immune system (e.g. drug induced, infection)~* Skin diseases that might interfere with response evaluation of study treatment~* Topical pretreatment of the AK study lesions with photodynamic therapy, Aldara®, Solaraze® 3% gel , 5-FU, or polyphenon E during the 8 weeks preceding study treatment~* Systemic treatment with cytostatic drugs or radiation therapy performed in the treatment area during the 3 months preceding study therapy~* Systemic treatment with diclofenac~* Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel~* Conditions that might interfere with the ability to understand the study and thus give written informed consent~* Simultaneous participation in another clinical study or participation in another clinical study in participation in another clinical study in the 30 days directly preceding inclusion~* Suspected lack of compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diclofenac (Type: EXPERIMENTAL): 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.

Based on this trial design, predict the completion outcome and termination type (if applicable).